|Day Low/High||3.52 / 3.82|
|52 Wk Low/High||2.50 / 14.84|
I stopped out of Lantheus Holdings for a small loss and bought Baozun near $15.
Preclinical Data for ANAVEX 1066 Presented at Society for Neuroscience Annual Meeting
The most recent short interest data has been released for the 10/14/2016 settlement date, which shows a 883,721 share increase in total short interest for Anavex Life Sciences Corp , to 5,641,528, an increase of 18.57% since 09/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
These under-$10 stocks are within range of triggering breakout trades. Here's how to trade them from here.
Here's a technical look at how to trade some of the most active stocks on the market right now.
Anavex (AVXL) announced on Thursday its Anavex 2-73 Parkinson's treatment was successful in a preclinical study.
Michael J. Fox Foundation funded ANAVEX 2-73 drug candidate study presented at World Parkinson Congress 2016
Conference to Feature Companies with Focus on Alzheimer's, Parkinson's and other Neurological Diseases
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Anavex Life Sciences Corp , where a total volume of 10,707 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 90.4% of AVXL's average daily trading volume over the past month, of 1.2 million shares.
A small group of Alzheimer's patients treated with Anavex 2-73 are exhibiting signs of memory loss, faltering cognition and inability to take care of themselves over time.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Anavex Life Sciences Corp , where a total of 3,227 contracts have traded so far, representing approximately 322,700 underlying shares. That amounts to about 41.6% of AVXL's average daily trading volume over the past month of 776,365 shares.
These stocks look ready to break out and trade higher from current levels.
Shared clinical phenotypes and underlying pathophysiology of Autism-Related Disorders such as Fragile X and Rett syndrome, indicates that ANAVEX 2-73 could be of interest to investigate clinically in these disorders
Detailed Data to be Presented at Upcoming Scientific Meeting